Genetron Health to Present at Canaccord Genuity 40th Annual Growth Conference
July 29 2020 - 4:39PM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ:GTH), a leading precision oncology platform company in China
that specializes in offering molecular profiling tests, today
announced that management will present and host one-on-one meetings
at the Canaccord Genuity 40th Annual Growth Conference to be held
virtually on August 11-13, 2020.
On Thursday, August 13th, the Genetron
management will participate in the following:
- Fireside chat at 8:00 am ET (8:00 pm Beijing time) with Sizhen
Wang, Chief Executive Officer
- Panel discussion entitled, “Cancer screening for asymptomatic
individuals. Single vs. multi-target testing; different
technological approaches; and opportunities/challenges to drive
broad-based adoption,” at 11:00 am ET (11:00 pm Beijing Time) with
Yun-Fu Hu, PhD, Chief Medical Officer
A webcast of the presentation will be available
on the "News and Events" page of the Investors section of the
Company's website. A replay of each webcast will be available for
30 days following the event. For more information, please visit
https://ir.genetronhealth.com/investors.
About Genetron Holdings
Limited
Genetron Holdings Limited (“Genetron Health” or
the “Company”) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron also partners with
global biopharmaceutical companies and offers customized services
and products. For more information, please visit
ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking
statements. These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Statements that are not historical facts, including
statements about the Company’s beliefs and expectations, are
forward-looking statements. Forward-looking statements involve
inherent risks and uncertainties, and a number of factors could
cause actual results to differ materially from those contained in
any forward-looking statement. In some cases, forward-looking
statements can be identified by words or phrases such as “may”,
“will,” “expect,” “anticipate,” “target,” “aim,” “estimate,”
“intend,” “plan,” “believe,” “potential,” “continue,” “is/are
likely to” or other similar expressions. Further information
regarding these and other risks, uncertainties or factors is
included in the Company’s filings with the SEC. All information
provided in this press release is as of the date of this press
release, and the Company does not undertake any duty to update such
information, except as required under applicable law.
Investor Relations
ContactsUS:Hoki LukHead of Investor RelationsEmail:
hoki.luk@genetronhealth.comPhone: +1 (408) 204-5343
Stephanie CarringtonWestwicke, an ICR CompanyEmail:
Stephanie.Carrington@westwicke.comPhone: +1 (646) 277-1282
Asia:Bill ZimaICR, Inc.Email:
bill.zima@icrinc.comGenetronIR@icrinc.com
Media Relations ContactEdmond
LococoICREdmond.Lococo@icrinc.comMobile: +86
138-1079-1408genetron.pr@icrinc.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024